BRPI0819210A2 - Anticorpos de proteína g anti-rsv - Google Patents

Anticorpos de proteína g anti-rsv

Info

Publication number
BRPI0819210A2
BRPI0819210A2 BRPI0819210-3A BRPI0819210A BRPI0819210A2 BR PI0819210 A2 BRPI0819210 A2 BR PI0819210A2 BR PI0819210 A BRPI0819210 A BR PI0819210A BR PI0819210 A2 BRPI0819210 A2 BR PI0819210A2
Authority
BR
Brazil
Prior art keywords
rsv
protein antibodies
antibodies
protein
Prior art date
Application number
BRPI0819210-3A
Other languages
English (en)
Inventor
Lawrence M Kauvar
Ellen J Collarini
Bruce Keyt
Orit Foord
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of BRPI0819210A2 publication Critical patent/BRPI0819210A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
BRPI0819210-3A 2007-10-25 2008-10-24 Anticorpos de proteína g anti-rsv BRPI0819210A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US8940108P 2008-08-15 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (1)

Publication Number Publication Date
BRPI0819210A2 true BRPI0819210A2 (pt) 2015-06-23

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819210-3A BRPI0819210A2 (pt) 2007-10-25 2008-10-24 Anticorpos de proteína g anti-rsv

Country Status (14)

Country Link
US (3) US7736648B2 (pt)
EP (1) EP2214711B1 (pt)
JP (2) JP5808536B2 (pt)
KR (1) KR101671452B1 (pt)
CN (1) CN101808663B (pt)
AU (1) AU2008316703B2 (pt)
BR (1) BRPI0819210A2 (pt)
CA (1) CA2703667C (pt)
IL (1) IL205257A (pt)
MX (1) MX2010004482A (pt)
NZ (1) NZ585589A (pt)
RU (1) RU2526517C2 (pt)
WO (1) WO2009055711A2 (pt)
ZA (1) ZA201003131B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
US7736648B2 (en) * 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
EP2780366A2 (en) 2011-11-17 2014-09-24 AIMM Therapeutics B.V. Rsv g protein specific antibodies
AU2013206789B2 (en) * 2011-12-28 2017-04-13 Immunoqure Ag Method of isolating human antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
US10196438B2 (en) 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
AU2014255865B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
CN105992772A (zh) * 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA多特异性结合分子
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
KR20230159637A (ko) 2014-12-05 2023-11-21 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
HUE057777T2 (hu) 2014-12-05 2022-06-28 Memorial Sloan Kettering Cancer Center Kiméra antigén receptorok, amelyek G-fehérje-kapcsolt receptort céloznak meg, és a receptorok alkalmazásai
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
CA3041717A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
EP3573651A4 (en) 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
CA3079604A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
WO2020023847A1 (en) 2018-07-27 2020-01-30 Ngm Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
EP3833677A4 (en) * 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED PASSIVE AND ACTIVE VACCINES AGAINST RSV
US20220362371A1 (en) * 2019-09-20 2022-11-17 Universiteit Antwerpen Human respiratory syncytial virus strain and its use
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734263B2 (ja) * 1993-05-25 2006-01-11 ワイス・ホールディングズ・コーポレイション 呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
AU770737B2 (en) 1999-01-22 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
ATE412666T1 (de) * 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EP2004686A1 (en) * 2006-03-06 2008-12-24 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
JP2009544014A (ja) 2006-07-12 2009-12-10 トレリス バイオサイエンス、インク． セルスポット・アプリケーション
US7736648B2 (en) * 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies

Also Published As

Publication number Publication date
CN101808663A (zh) 2010-08-18
US20100285022A1 (en) 2010-11-11
CA2703667A1 (en) 2009-04-30
RU2010120879A (ru) 2011-11-27
RU2526517C2 (ru) 2014-08-20
KR101671452B1 (ko) 2016-11-17
EP2214711A4 (en) 2011-12-21
NZ585589A (en) 2012-07-27
MX2010004482A (es) 2010-07-06
EP2214711A2 (en) 2010-08-11
IL205257A (en) 2014-12-31
US9321830B2 (en) 2016-04-26
WO2009055711A2 (en) 2009-04-30
AU2008316703A1 (en) 2009-04-30
IL205257A0 (en) 2010-12-30
US8273354B2 (en) 2012-09-25
US20090130120A1 (en) 2009-05-21
CN101808663B (zh) 2015-09-30
AU2008316703B2 (en) 2012-09-27
JP2015078231A (ja) 2015-04-23
US20130034564A1 (en) 2013-02-07
CA2703667C (en) 2015-12-29
JP5808536B2 (ja) 2015-11-10
US7736648B2 (en) 2010-06-15
KR20100091195A (ko) 2010-08-18
JP2011500091A (ja) 2011-01-06
WO2009055711A3 (en) 2009-09-24
ZA201003131B (en) 2011-03-30
AU2008316703A2 (en) 2010-07-22
EP2214711B1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0918947A2 (pt) proteína de fusão de anticorpo
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0819165A2 (pt) Anticorpos anti-vegf
BRPI0820073A2 (pt) Anticorpos anti-axl
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK3118220T3 (da) Protein
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
DK2046826T3 (da) Exendin-fusionsproteiner
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0820819A2 (pt) Formulação de anticorpos
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
NO344963B1 (no) Humanisert antistoff
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0810482A2 (pt) Métodos de produção de proteína usando compostos antissenescência
DK1999154T3 (da) Fremstillede heterodimere proteindomæner
BRPI0821532A2 (pt) Antígenos de rsv recombinantes
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0922730A2 (pt) formulação de anticorpo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/10 (2006.01), A61K 39/00 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2485 DE 21-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.